Compare RDN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDN | ADPT |
|---|---|---|
| Founded | 1977 | 2009 |
| Country | United States | United States |
| Employees | N/A | 624 |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.6B |
| IPO Year | 2008 | 2019 |
| Metric | RDN | ADPT |
|---|---|---|
| Price | $34.88 | $28.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $40.67 | $17.78 |
| AVG Volume (30 Days) | 903.3K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | 5.61 | ★ 63.89 |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $1,197,084,000.00 | $276,976,000.00 |
| Revenue This Year | N/A | $3.98 |
| Revenue Next Year | $2.66 | $22.72 |
| P/E Ratio | $20.00 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $31.50 | $12.00 |
| 52 Week High | $41.05 | $28.72 |
| Indicator | RDN | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 35.65 | 73.30 |
| Support Level | $31.87 | $23.73 |
| Resistance Level | $37.34 | N/A |
| Average True Range (ATR) | 0.68 | 1.13 |
| MACD | -0.12 | 0.34 |
| Stochastic Oscillator | 22.87 | 95.95 |
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.